The Food and Drug Administration recently released proposed language on laboratory developed tests (LDTs). Hear from a panel of experts on how the proposed rule might impact clinicians, patients, and innovators, and suggestions for ways to improve the language. 

Speakers:

Bruce Quinn, MD, PhD, Principal, Bruce Quinn Associates LLC

Sandra Waugh Ruggles, PhD, Director of Policy Research, Stanford Biodesign

Additional speakers to be announced

Moderated By:

Kavita Patel, MD, MS, FACP, Director, Policy Program, Stanford Biodesign; Professor of Medicine, Stanford University